XML 25 R10.htm IDEA: XBRL DOCUMENT
v3.21.1

Fair Value Measurements | 3 Months Ended
--- | ---
Mar. 31, 2021
Fair Value Disclosures [Abstract] |
Fair Value Measurements | Fair Value Measurements We record cash equivalents and investments in debt securities available-for-sale and equity securities at fair value based on a fair value hierarchy that distinguishes between assumptions based on market data (observable inputs) and our own assumptions (unobservable inputs). The fair value hierarchy consists of the following three levels: Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 – Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 – Unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing the asset or liability when there is little, if any, market activity for the asset or liability at the measurement date. Investments in debt securities available-for-sale are classified as Level 2 and carried at fair value. We estimate the fair value of debt securities available-for-sale by utilizing third-party pricing services. These pricing services utilize industry standard valuation models, including both income and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. Such inputs include market pricing based on real-time trade data for similar instruments, issuer credit spreads, benchmark yields, broker/dealer quotes and other observable inputs. We validate valuations obtained from third-party pricing services by understanding the models used, obtaining market values from other pricing sources, and analyzing data in certain instances. Investments in equity securities of certain companies that are subject to holding period restrictions longer than one year are classified as Level 3 and carried at fair value using an option pricing valuation model. The most significant assumptions within the option pricing valuation model are the stock price volatility, which is based on the historical volatility of similar companies, and the discount for lack of marketability related to the term of the restrictions. The carrying amounts of accounts receivable and accounts payable and accrued liabilities approximate their fair values due to their short-term maturities. Investments at March 31, 2021, which were measured at fair value on a recurring basis, consisted of the following:
|  |  | Fair Value Measurements Using
(in millions) | Fair Value |  | Level 1 |  | Level 2 |  | Level 3
Cash and cash equivalents: |  |  |  |  |  |  |
Cash and money market funds | $ | 352.6 |  |  | $ | 352.6 |  |  | $ | — |  |  | $ | — |
Total cash and cash equivalents | 352.6 |  |  | 352.6 |  |  | — |  |  | — |
Restricted cash: |  |  |  |  |  |  |
Certificates of deposit | 3.2 |  |  | 3.2 |  |  | — |  |  | — |
Total restricted cash | 3.2 |  |  | 3.2 |  |  | — |  |  | — |
Debt securities available-for-sale: |  |  |  |  |  |  |
Commercial paper | 93.2 |  |  | — |  |  | 93.2 |  |  | — |
Corporate debt securities | 409.4 |  |  | — |  |  | 409.4 |  |  | — |
Securities of government-sponsored entities | 268.1 |  |  | — |  |  | 268.1 |  |  | — |
Total debt securities available-for-sale | 770.7 |  |  | — |  |  | 770.7 |  |  | — |
Equity securities: |  |  |  |  |  |  |
Equity securities–biotechnology industry | 38.9 |  |  | — |  |  | — |  |  | 38.9 |
Total equity securities | 38.9 |  |  | — |  |  | — |  |  | 38.9 |
Total recurring fair value measurements | $ | 1,165.4 |  |  | $ | 355.8 |  |  | $ | 770.7 |  |  | $ | 38.9 |
Investments at December 31, 2020, which were measured at fair value on a recurring basis, consisted of the following:
|  |  | Fair Value Measurements Using
(in millions) | Fair Value |  | Level 1 |  | Level 2 |  | Level 3
Cash and cash equivalents: |  |  |  |  |  |  |
Cash and money market funds | $ | 187.1 |  |  | $ | 187.1 |  |  | $ | — |  |  | $ | — |
Total cash and cash equivalents | 187.1 |  |  | 187.1 |  |  | — |  |  | — |
Restricted cash: |  |  |  |  |  |  |
Certificates of deposit | 3.2 |  |  | 3.2 |  |  | — |  | —
Total restricted cash | 3.2 |  |  | 3.2 |  |  | — |  | —
Debt securities available-for-sale: |  |  |  |  |  |  |
Commercial paper | 82.2 |  |  | — |  | 82.2 |  |  | —
Corporate debt securities | 445.9 |  |  | — |  | 445.9 |  |  | —
Securities of government-sponsored entities | 312.9 |  |  | — |  | 312.9 |  |  | —
Total debt securities available-for-sale | 841.0 |  |  | — |  |  | 841.0 |  |  | — |
Equity securities: |  |  |  |  |  |  |
Equity securities–biotechnology industry | 38.2 |  |  | — |  | — |  | 38.2 |
Total equity securities | 38.2 |  |  | — |  | — |  | 38.2 |
Total recurring fair value measurements | $ | 1,069.5 |  |  | $ | 190.3 |  |  | $ | 841.0 |  |  | $ | 38.2 |
The following table presents a reconciliation of equity security investments, which were measured at fair value on a recurring basis using significant unobservable inputs (Level 3):
| Three Months Ended March 31, |  |
(in millions) | 2021 |  | 2020 |  |  |  |
Balance at beginning of period | $ | 38.2 |  |  | $ | 55.9 |  |  |  |  |
Unrealized gain (loss) included in earnings | 0.7 |  |  | (16.5) |  |  |  |  |
Balance at end of period | $ | 38.9 |  |  | $ | 39.4 |  |  |  |  |
At March 31, 2021, the discount for lack of marketability used in the valuation analysis of equity security investments ranged from 12.0% to 15.0% (weighted average of 13.3%). The discount for lack of marketability was weighted by the relative fair value of the instruments. A significant increase (decrease) in the discount for lack of marketability in isolation would result in a significantly lower (higher) fair value measurement. Unrealized gains and losses on equity security investments are included in other income (expense), net.

X
- References No definition available. + Details
Name: | us-gaap_FairValueDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258 + Details
Name: | us-gaap_FairValueDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration